Compare ARK Genomic Revolution ETF (ARKG) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Charles River Laboratories Intl. Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.51, while Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.24B). Which is the better fit depends on your goals.
| ARKG | CRL | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $233.60 |
52-Week Low | $23.09 | $145.57 |
Market Cap | — | $11.24B |
Enterprise Value | — | $14.11B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
